Literature DB >> 15170891

Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis.

Nicole Grois1, Daniela Prayer, Helmut Prosch, Milen Minkov, Ulrike Pötschger, Helmut Gadner.   

Abstract

BACKGROUND: Diabetes insipidus (DI) is the most frequent sequela in Langerhans cell histiocytosis (LCH). The clinical relevance and therapeutic impact of brain magnetic resonance imaging (MRI) findings in LCH patients with LCH during the disease course is unclear. PROCEDURE: In this retrospective study, we reviewed 113 brain MRIs from 59 DI patients, in 17 of these serial follow up MR-examination findings were correlated to the clinical course and therapy.
RESULTS: At DI diagnosis, 71% patients showed a thickened stalk, in 24% the stalk was still thickened on MRIs done more than 5 years after DI onset, and in two patients the stalk was already thickened several months before DI onset. The changes of the pituitary stalk thickness were highly variable and did not clearly correlate with the treatment. Regression of pituitary thickness on MRI did not concur with clinical recovery of DI, which persisted in all but one patient with initially partial DI. The occurrence of anterior pituitary hormone deficiencies appeared to be linked to a thickening of the stalk at DI diagnosis. LCH-lesions in the craniofacial bones were seen in 75% DI patients, and 76% of DI patients with follow up MRIs done 5 years or longer after DI diagnosis had parenchymal neurodegenerative brain changes.
CONCLUSIONS: Our study indicates that repeated MR-examinations in DI patients are of limited value for assessing a response to therapy in the pituitary stalk, but are important for the monitoring of craniofacial bone lesions and for the detection of parenchymal CNS disease. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15170891     DOI: 10.1002/pbc.20003

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.

Authors:  Yoko Shioda; Souichi Adachi; Shinsaku Imashuku; Kazuko Kudo; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

2.  Primary hypothyroidism, precocious puberty and hypothalamic obesity in Langerhans cell histiocytosis.

Authors:  Leena Priyambada; Vijayalakshmi Bhatia; Narendra Krishnani; Vinita Agarwal; Avik Bhattacharyya; Sunil Jain; S K Mishra; R K Marwaha
Journal:  Indian J Pediatr       Date:  2010-10-31       Impact factor: 1.967

3.  Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH).

Authors:  Polyzois Makras; Dimitrios Papadogias; George Kontogeorgos; George Piaditis; Gregory A Kaltsas
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Paediatric neuroradiological aspects of Langerhans cell histiocytosis.

Authors:  Philippe Demaerel; Stefaan Van Gool
Journal:  Neuroradiology       Date:  2007-11-06       Impact factor: 2.804

5.  Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis.

Authors:  Shinsaku Imashuku; Naoko Kudo; Shigehiro Kaneda; Hiroshi Kuroda; Tsuguka Shiwa; Tetsuya Hiraiwa; Atsushi Inagaki; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-10-21       Impact factor: 2.490

6.  Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH).

Authors:  P Makras; C Samara; M Antoniou; A Zetos; D Papadogias; Z Nikolakopoulou; E Andreakos; G Toloumis; G Kontogeorgos; G Piaditis; G A Kaltsas
Journal:  Neuroradiology       Date:  2005-11-15       Impact factor: 2.804

7.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

Review 8.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

9.  Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.

Authors:  Shinsaku Imashuku; Naoko Kinugawa; Akinobu Matsuzaki; Toshiyuki Kitoh; Kentaro Ohki; Yoko Shioda; Yukiko Tsunematsu; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2009-09-25       Impact factor: 2.490

10.  The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation.

Authors:  Neslihan Kurtulmus; Meral Mert; Refik Tanakol; Sema Yarman
Journal:  Endocrine       Date:  2014-09-11       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.